Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
APS | Toronto | CAD | Real-time | |
APTO | NASDAQ | USD | Real-time | |
APS | CBOE Canada | CAD | Real-time |
For the three months ended 31 March 2022, Aptose Biosciences Inc revenues was not reported. Net loss decreased 29% to $11.5M. Lower net loss reflects Stock-based compensation decrease of 70% to $1.6M (expense), Program costs Luxeptinib decrease of 29% to $2.8M (expense), Program costs APTO-253 decrease of 92% to $91K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.18 to -$0.12.
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Revenue | 0 | 0 | 0 | 0 |
Gross Profit | ||||
Operating Income | -11.5 | -24.35 | -11.36 | -13.49 |
Net Income | -11.48 | -24.32 | -11.33 | -13.47 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Assets | 72.6 | 82.53 | 97.2 | 106.21 |
Total Liabilities | 7.32 | 8.29 | 8.52 | 8.03 |
Total Equity | 65.28 | 74.24 | 88.68 | 98.19 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Period Length: | 3 Months | 12 Months | 9 Months | 6 Months |
Cash From Operating Activities | -9.64 | -43.3 | -27.26 | -19.2 |
Cash From Investing Activities | 7.5 | -35.21 | -15.2 | -15.01 |
Cash From Financing Activities | 0.01 | 0.23 | 0.16 | 0.16 |
Net Change in Cash | -2.12 | -78.28 | -42.3 | -34.05 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review